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Abstract
In the mouth, melanin is produced by melanocytes residing in the basal cell layer of 
the oral epithelium. Melanin influences the colour of the oral mucosa and provides pro-
tection against reactive oxygen species and bacterial-derived enzymes and toxins and 
acts as a physical barrier to both microorganisms invading the oral epithelium and to 
other microenvironmental stressors. The functional activity of epithelial melanocytes is 
regulated by biological agents in the microenvironment, including proopiomelanocortin-
derived peptides, and by reciprocal interactions between melanocytes on the one hand 
and neighbouring keratinocytes and signals from the underlying lamina propria on the 
other hand. Oral mucosal melanin hyperpigmentation is common and may be physi-
ological or pathological, and in either case the pattern of distribution and the intensity 
of the melanosis are variable. Physiological melanin hyperpigmentation is the result of 
increased melanin biosynthesis by melanocytes in the basal cell layer of the oral epithe-
lium, but pathological melanin pigmentation may be the result of increased number of 
normal melanocytes or atypical melanocytes, of increased melanogenic activity of nor-
mal or atypical melanocytes, or of both. Oral mucosal melanin hyperpigmentation may 
be secondary to disease, medications, or smoking, and physiological oral melanin hyper-
pigmentation may be clinically and histopathologically similar so that the differentiation 
between pathological and physiological oral melanosis can at times be difficult.
Keywords: oral mucosa, melanocytes, melanosomes, melanotic macule, melanoma, 
naevus, physiological oral pigmentation
1. Introduction
There are both melanin-producing and amelanotic melanocytes in the oral stratified squa-
mous epithelium, and the degree of melanin pigmentation of the oral mucosa is genetically 
determined. Dark-skinned persons more often have physiological oral mucosal melanin 
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hyperpigmentation than do light-skinned persons. Regardless of race/ethnicity, the number 
and the distribution of melanocytes are very much the same within each oral anatomical 
region but vary from region to region. Even when there is no obvious pigmentation, oral 
mucosal melanocytes are always present and produce some melanin but the amount pro-
duced is determined by their melanogenic activity [1–4].
The vascularity, the blood haemoglobin concentration, the degree of keratinization of the epi-
thelium, and the type and amount of melanin pigment present are variable determinants of 
the colour of the oral mucosa. The degree of melanin pigmentation per se is determined by the 
number and distribution of melanocytes in the basal cell layer of the oral epithelium of each 
anatomical region, by their melanogenic activity, by the degree of arborisation of the den-
dritic processes of the melanocytes, and by the number, size, and distribution of melanosomes 
in the ‘melanocyte-keratinocyte unit’ [4–6].
Most of the information on the physiology of oral mucosal melanocytes is derived from 
research on epidermal melanocytes. Oral mucosal and epidermal melanocytes are histologi-
cally and ultrastructurally similar, but under physiological conditions, it seems that the for-
mer are intrinsically less metabolically active. However, in response to chemical or physical 
environmental triggers, to certain drugs and hormones, to inflammation, and in association 
with certain systemic diseases or neoplastic processes, the metabolism of oral melanocytes 
may increase with consequent increase in biosynthesis of melanin [4, 6]. The intracellular 
and the microenviromental molecular signalling pathways that drive the development of oral 
mucosal melanin pigmentation remain largely unknown [7].
Brown/black eumelanin and yellow/red pheomelanin are pigmented polymers synthesized in 
unique organelles called melanosomes within melanocytes. Melanin has the capacity to scav-
enge reactive oxygen species and to neutralize microorganisms and their harmful products. 
Melanocytes also contribute to the homeostasis of skin and oral mucosa by acting as neuroen-
docrine cells secreting neuropeptides and as antigen presenting cells and phagocytes [4, 6, 8, 9].
Upregulation of melanin biosynthesis or increase in the number either of normal or of atypi-
cal oral mucosal melanocytes may bring about oral mucosal melanin hyperpigmentation. 
Physiological and pathological oral mucosal melanin hyperpigmentations may be similar in 
appearance, and sometimes may be difficult to differentiate even on the basis of history and 
microscopical features. Pathological oral mucosal melanin hyperpigmentations include those 
related to tobacco smoke, to certain systemic diseases or syndromes, to inflammatory pro-
cesses, to certain drugs, and to developmental, benign, or malignant changes in melanocytes 
[4, 6, 10–13].
Engaging in any clinical or histopathological study on oral mucosal melanin hyperpigmenta-
tion is complex. Many subjects with oral mucosal melanin hyperpigmentation, whether phys-
iological or pathological in origin, are usually unaware of it so cannot give information about 
its duration or progression. Oral mucosal melanin hyperpigmentation secondary to disease 
and physiological oral mucosal melanin hyperpigmentation may be clinically and histopatho-
logically similar, and in some cases, it is almost impossible to determine whether oral mucosal 
melanin hyperpigmentation is physiological or is induced by smoking, by drugs, or by both.
Melanin8
Not all biological, physical, or chemical factors that may promote melanogenesis are known, 
neither are all the factors that may influence the size, distribution, or intensity of areas of oral 
pigmentation. Further research is needed to elucidate these issues; and into the roles that 
melanocytes and melanin play in the maintenance of homeostasis of the oral mucosa, as well 
as into the roles physiological or benign oral mucosal melanin hyperpigmentations may play 
as precursors of premalignant and malignant oral melanotic lesions.
In this chapter, we briefly review some aspects of the biology and physiology of oral melano-
cytes, the function of melanin in the oral epithelium, and the features of several different oral 
mucosal melanin hyperpigmentations, including physiological hyperpigmentation, tobacco-
related melanosis, human immunodeficiency virus (HIV)-associated melanosis, melanotic 
maculae, naevomelanocytic naevus, and oral mucosal melanoma.
2. The biology of oral melanocytes
Melanocytes originate from neural crest precursor cells, which during embryogenesis migrate 
from the neural crest to their ultimate destination in the basal cell layer of the epidermis and 
of the epithelium of mucous membranes where they differentiate into mature melanin-pro-
ducing melanocytes with complex network of dendritic processes [14]. However, some neural 
crest cells in their process of migration to the epithelium may become arrested in the lamina 
propria/dermis, remaining there in an immature state. These arrested immature melanocytes 
also sometimes termed naevomelanocytes, can become active, forming nests of cells giving 
rise to dermal/intra lamina propria naevi, and rarely to melanomata at those sites [15].
It is not clear whether the replacement of melanocytes of the basal cell layer of the oral epi-
thelium lost to physiological processes of apoptosis or senescence, or to mechanical, thermal, 
or chemical injury is the result of cell division of ‘mature’ melanocytes in the basal cell layer 
of the oral epithelium which still retain their capacity of replication, or a result of migration 
from their local niche reservoirs of melanocyte stem/progenitor cells and their subsequent 
proliferation [6].
The mechanism by which the population of melanocytes of the oral epithelium is main-
tained in a steady state is unknown [7]. While melanocyte stem/progenitor cells and their 
reservoir niche have been identified in the skin, in the oral mucosa they have not been found 
[6, 15]. Tissue-specific melanocyte stem/progenitor cells are, however, relatively undiffer-
entiated, divide infrequently, and have the capacity for self-renewal thus maintaining the 
genetic information necessary for regeneration of the population of melanin-producing 
melanocytes [16].
The ratio of melanocytes to keratinocytes in the basal cell layer of the oral epithelium, mea-
sured linearly, ranges from 1:10 to 1:15 [17]. However, this ratio varies at different oral 
mucosal sites of the same persons, but is similar in the same oral sites of different persons, 
regardless of their race/ethnicity [18, 19]. Melanocytes in the basal cell layer of the epithe-
lium are connected to and communicate with their immediate neighbouring keratinocytes by 
means of tight junctions and gap junctions. Expression of E-cadherin cell adhesion molecules 
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 suppresses  melanocyte proliferation, but on the other hand, expression of N-cadherin trig-
gered by trauma or metabolic changes in the microenvironment promotes proliferation and 
migration of melanocytes, which can then aggregate in nests [4, 6].
It has been suggested that keratinocytes, through the release of biological mediators, proo-
piomelanocortin (POMC)-derived peptides, basic fibroblast growth factor, and endothe-
lins, regulate proliferation and differentiation of melanocytes and stimulate melanogenesis 
through receptor-mediated signalling pathways [20].
Melanin is produced in melanosomes within the melanocytes in the basal cell layer of the 
oral epithelium. Mature melanin-containing melanosomes are transported from a perinuclear 
position in the cytoplasm of the melanocytes into and along microtubules towards the end 
of the dendritic processes, borne by the motor proteins kinesin and dynein. At the tip of the 
arborising dendritic processes, the melanosomes are transferred to neighbouring keratino-
cytes [4, 6, 21, 22]. It appears that each melanocyte is in contact with about 35 neighbouring 
keratinocytes in the basal and suprabasal cell layers of the epithelium, each forming a ‘mela-
nocyte-keratinocyte unit’ [4, 6, 7].
3. Functions of melanocytes
Melanin influences the colour of the skin, oral mucosa, hair, and eyes. Melanin can also inacti-
vate reactive oxygen species and free radicals, can sequestrate redox-active metals and organic 
toxic compounds, can neutralize bacteria-derived enzymes and toxins, and can downregulate 
inflammatory processes [4, 6, 7].
In the process of ascending through the cell layers of the epithelium to the surface desquamat-
ing layer, melanosomes lost from keratinocytes that form part of the melanocyte-keratinocyte 
unit disintegrate, releasing melanin ‘dust’ into the microenvironment. As melanin has strong 
binding properties, it can act as a physical barrier to both microorganisms invading the skin 
or mucous membrane and to other environmental stressors [4, 6, 7].
Although melanin itself provides protection against reactive oxygen species (ROS) and toxic 
free radicals, paradoxically, the biosynthesis of melanin itself generates ROS that may cause 
DNA damage; and quinones and semiquinones, which are intermediates of melanin bio-
synthesis, are mutagenic with the capacity to cause cytogenetic instability. Therefore, loss of 
the integrity of melanosome membranes with leakage of these intrinsic toxic agents has the 
potential to cause self-injury to the melanocytes [6].
Apart from the beneficial effects and detrimental side effects of melanin production, mela-
nocytes can also protect against microbial infections by acting as antigen-presenting cells 
producing cytokines, phagocytosing microorganisms, and degrading both phagocytosed 
bacteria and bacteria in the microenvironment by means of melanosomal lysosomal enzymes 
[4, 6, 7].
Melanocytes can also function as neuroendocrine cells by producing acetylcholine, cat-
echolamines, and POMC-derived peptides, which have the capacity to mediate local 
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 immunoinflammatory and antimicrobial responses and to modulate the biological behav-
iour of oral tissues [4]. Melanocytes function as stress sensors, as immunocytes, and as 
neuroendocrine cells, thus playing several important roles in maintaining tissue homeo-
stasis [23–25].
The functional activity of epithelial melanocytes is regulated by the reciprocal interaction 
of melanocytes in the basal cell layer of the epithelium with the underlying lamina-proprial 
connective tissue and by several other biological agents. These include the POMC-derived 
peptides released by neighbouring keratinocytes and the neuropeptide calcitonin gene-
related peptide, substance P, and neuropeptide Y released from intramucosal free nerve end-
ings, which are in close contact with melanocytes in the basal cell layer of the epithelium. 
Adrenergic and cholinergic agents, growth factors, inflammatory mediators, and other auto-
crine and endocrine stimuli also contribute to the regulation of the functional activity of mela-
nocytes [6].
4. Melanin biosynthesis
Premelanosomes contain all the proteins and enzymes required for their maturation to the 
fully functional specialised membrane-bound organelles called melanosomes, which are the 
sites of biosynthesis of melanin [26, 27]. The fully functional melanosomes contain all the 
proteins and enzymes required for biosynthesis of melanin, and the structural matrix proteins 
form an internal scaffold both to support the architecture of the melanosomes and to serve as 
a nidus for melanin deposition [22].
The melanosomes in melanocytes residing in the basal cell layer of the epithelium can syn-
thetise two chemically distinct types of melanin: brown/black eumelanin and red/yellow 
pheomelanin, both of which are derivatives of the amino acid tyrosine through the inter-
mediate step of conversion of dopa to dopamine [4]. Both eumelanin and pheomelanin 
can be produced in the same melanocyte, but by different melanosomes. Eumelanosomes 
and pheomelanosomes differ in shape and in their patterns of internal melanin deposition. 
Eumelanosomes are elliptical and characterized by longitudinal deposition of the pigment; 
and pheomelanosomes are spherical, characterized by granular deposition of the melanin 
[4]. The ratio of eumelanin to pheomelanin is genetically determined by a number of factors 
including the degree of base-line functional activity of the enzymes and proteins driving the 
‘mixed melanogenesis’, by the melanocortin 1 receptor (MC1R) genetic polymorphism, and 
by the amount of the tyrosine in the melanosome [6].
The following agents are important in melanin biosynthesis. Tyrosinase drives the complex 
conversion of tyrosine to melanin. p protein is involved in stabilizing the melanosomal pro-
tein complex, in regulating the melanosomal pH, and in transporting the requisite proteins 
to the melanosomes. Tyrosinase-related protein 1 stabilizes the enzyme tyrosinase and is 
involved in melanosome maturation, and tyrosinase-related protein 2 modulates the quantity 
and quality of the melanin produced. The membrane-associated transport protein (MATP) 
functions as its name implies [5, 28].
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5. Regulation of melanin biosynthesis and distribution
Upregulation of melanin biosynthesis may be triggered by external stimuli, such as radia-
tion, tobacco smoke, certain drugs, and endogenous paracrine and endocrine agents. POMC-
derived peptides including adrenocorticotropin (ACTH), alpha melanocyte stimulating 
hormone (α-MSH), β-MSH and β-endorphins, MC1R, adrenergic and cholinergic agents, and 
growth factors, cytokines, or nitric oxide (NO) secreted in the local microenvironment are all 
involved in the regulation of melanogenesis [6].
POMC-derived peptides, particularly α-MSH, stimulate MC1R of melanocytes, releasing 
the intracellular second messenger cAMP, which in turn induces a cascade of intracellular 
molecular events, ultimately activating the microphthalmia-associated transcription factor 
(MITF). This is the master regulator of genes driving the process of melanogenesis. Thus, the 
α-MSH/MC1R/cAMP/MITF molecular signalling pathway is fundamental to melanin biosyn-
thesis and to a great extent determines the type and amount of the melanin produced [4, 6]. 
The MC1R gene is highly polymorphic; the most common MC1R variant promotes eumela-
nin production, but other germline variants are associated with increased pheomelanin and 
decreased eumelanin biosynthesis [6].
β-endorphin, the POMC-derived opioid peptide, has the capacity to upregulate melanogen-
esis and melanin distribution by promoting maturation of melanocytes and arborisation of 
their dendritic processes, thus increasing the efficacy of the transfer and distribution of mela-
nosomes to neighbouring keratinocytes [23, 29].
Non-neural adrenergic and cholinergic signalling pathways are expressed by mela-
nocytes. Activation of adrenalin/β2-adrenoreceptor/cAMP/MITF and of noradrenalin/
α1-adrenoreceptor/cAMP/MITF also induces melanin biosynthesis and arborisation of mela-
nocytic dendrites. Activation of nicotine receptors on oral melanocytes by acetylcholine or by 
nicotine may bring about melanin hyperpigmentation [4, 6, 30].
Inflammatory mediators can induce production of prostaglandin E2 (PGE2) and NO, which in turn have the capacity to promote maturation and increase transport of melanosomes, to 
upregulate the expression of the tyrosinase gene, and to increase the complexity of the net-
work of melanocytic dendrites. PGE2 and NO together promote melanogenesis and melanin deposition [4, 6, 31, 32].
To the best of our knowledge, the role that the melanocortin, adrenergic, and cholinergic 
systems play in relation to melanogenesis in the oral mucosa has not been demonstrated, and 
current knowledge of these systems is from research on epidermal melanin.
6. Oral mucosal melanin hyperpigmentation
Oral mucosal melanin hyperpigmentation is common and may be physiological (racial) or path-
ological [4, 6]. In either case, the pattern of distribution and the intensity of the pigmentation are 
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variable. The pigmentation may be the result of an increase in the number of melanocytes in the 
basal cell layer of the oral epithelium, or of increased melanin biosynthesis by the melanocytes. 
Sometimes pathological hyperpigmentation may be brought about by hyperplasia or increased 
melanogenesis of atypical melanocytes [33]. Melanogenically active melanocytes/nevomelano-
cytes in the lamina propria also have the capacity to cause oral mucosal melanin hyperpigmen-
tation [34]. Occasionally histopathological examination of a biopsy specimen from a pigmented 
lesion is needed to rule out a malignancy.
6.1. Physiological oral mucosal melanin hyperpigmentation
Physiological oral mucosal melanin hyperpigmentation manifests clinically as asymptomatic, 
single or multiple, well-demarcated or ill-defined patchy or uniform macules which range in 
colour from light to dark brown or black, and are of variable size and configuration. It may 
affect any part of the oral mucosa, but most frequently the gingiva, where it is usually bilat-
erally symmetrical, does not transgress the mucogingival junction, and does not involve the 
marginal gingiv (Figure 1) [4, 6]. Physiological gingival melanin hyperpigmentation is often 
more pronounced in the anterior than in the posterior part of the mouth, and the buccal/labial 
surfaces are more intensely pigmented than the lingual/palatal [35].
Physiological oral mucosal melanin hyperpigmentation is very common in Blacks, in general 
is more frequent in darker-skinned than in lighter-skinned persons regardless of their race/
ethnicity, and is most probably caused by genetically determined metabolic hyperactivity 
of oral melanocytes. It affects males and females equally and usually develops during the 
first three decades of life. Many persons with oral mucosal melanin hyperpigmentation are 
unaware of its presence [7]. According to some publications, the extent and the intensity of 
physiological oral mucosal melanin hyperpigmentation increase with age probably owing to 
the cumulative effects of endogenous and extrinsic melanogenic stimuli, such as inflamma-
tory processes, drugs, tobacco smoke, and recurrent minor functional injuries [4, 6, 11, 13].
Figure 1. Generalized black-brown physiological melanin hyperpigmentation of the maxillary and mandibular gingiva, 
not transgressing the mucogingival junction. The patient’s main concern was her carious incisors.
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In physiological oral mucosal melanin hyperpigmentation there is no increase in the number 
of melanocytes, but there is increased melanin in melanocytes in the basal cell layer of the oral 
epithelium, in the ‘melanocyte-keratinocyte units’, and in the lamina propria within melano-
phages. Occasionally, extracellular particles of pigment may be observed. These microscopi-
cal features are very similar to those observed in idiopathic melanotic macules, in melanosis 
related to smoking tobacco or inflammation, in melanosis induced by certain medications, 
and in HIV melanosis [11, 36]. Therefore, a thorough medical history may be helpful for dif-
ferential diagnosis, but the differentiation of physiological oral mucosal melanin hyperpig-
mentation from single or multiple melanotic macules based on medical history and on clinical 
and histological grounds may be impossible as they share the same clinical and microscopi-
cal features and both may develop at a young age. It is also almost impossible to determine 
whether the oral mucosal melanin hyperpigmentation in an HIV-seropositive smoker who 
is on multiple drug therapy is owing to the medication, to the HIV infection, to the use of 
tobacco, or to the interaction between these factors.
Physiological melanin hyperpigmentation does not require treatment, but if for cosmetic 
reasons it has to be removed, laser or cryotherapy or surgical excision are often successful. 
However, recurrence is not uncommon most probably because treatment does not always 
completely eliminate the genetically programmed hyperactive melanocytes in the epithelial 
field surrounding the hyperpigmentation [4].
6.2. Inflammation-associated oral mucosal melanin hyperpigmentation
Under circumstances that are not well defined, certain inflammatory cytokines and media-
tors have the capacity to promote the production of α-MSH by oral melanocytes and kera-
tinocytes and to upregulate the expression of MC1R of melanocytes resulting in increased 
biosynthesis of melanin. Independently of this α-MSH/MC1R pathway, PGE2 can promote tyrosinase activity and arborisation of melanocytic dendrites. Thus, melanin hyperpigmenta-
tion may develop at chronically inflamed oral mucosal sites, as in association with repetitive 
local trauma or injury or with immunoinflammatory pathological conditions, such as oral 
lichen planus and oral lichenoid reactions [37].
Such inflammation-associated oral mucosal melanin hyperpigmentation occurs most com-
monly in darker skinned persons and usually manifests as single or multiple brown-black 
patches, which may persist for a long time after the resolution of the inflammatory process 
[6, 11, 37]. These inflammation-associated hyperpigmented patches are of no clinical signifi-
cance, their biological significance is unknown, and treatment is not required.
6.3. Tobacco-related oral melanosis
Tobacco smoking may cause diffuse brown-black hyperpigmentation of the oral mucosa in 
20–30% of chronic heavy smokers. This usually affects the gingiva, palate, and the buccal 
mucosa, and the intensity of the pigmentation is related to total tobacco usage. It has been 
suggested that the melanin produced in response to cigarette smoking is a protective reac-
tion, contributing to the detoxification of polyaromatics, nicotine, and benzopyrene in the 
tobacco smoke. Smoker’s melanosis may gradually diminish if the smoking habit is stopped. 
Importantly, smoker’s melanosis does not undergo malignant transformation [11, 36].
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As in differentiating some other cases of oral mucosal melanin hyperpigmentations one from 
another, on clinical and histological grounds alone it is impossible to make a positive diagno-
sis of tobacco-related melanosis.
6.4. Human immunodeficiency virus (HIV)-associated and medication-induced oral 
mucosal melanin hyperpigmentations
Oral melanin hyperpigmentation is common in HIV-seropositive subjects. It may develop 
secondarily to HIV-induced cytokine dysregulation, to medications used in the treatment 
of HIV infection or HIV-associated diseases (zidovudine, clofazimine and ketoconazole), or 
to adrenocortical deficiency, which is not infrequent in HIV-seropositive subjects with a low 
CD4+ T cell counts [6, 10].
It is unknown whether structural proteins of HIV can stimulate melanocyte activity directly 
to upregulate their melanin biosynthesis. It is possible that HIV-associated mucosal hyper-
pigmentation may fortuitously represent a local protective immune reaction against 
subclinical oral infections and concomitant inflammatory processes. Indeed, it has been 
suggested that certain cytokines that are upregulated during HIV infection have the capac-
ity to induce the production of α-MSH by oral melanocytes and keratinocytes and to medi-
ate the upregulation of expression of MC1R by melanocytes, resulting in increased melanin 
production. In some HIV-seropositive subjects, this may trigger oral mucosal melanin 
hyperpigmentation [6, 14].
If it occurs, HIV-associated oral mucosal melanin hyperpigmentation usually develops within 
2 years of contracting HIV or within a few months of starting antiretroviral treatment with the 
drug zidovudine. Typically, it manifests clinically either as solitary or multiple dark melanotic 
macules (Figure 2a, b) or as diffuse brownish or brown-black areas of melanin hyperpigmen-
tation (Figure 3). This may involve any part of the oral mucosa but most frequently the buccal 
mucosa, affecting females and males equally [6, 14].
Figure 2. (a) Multiple pigmented maculae of the maxillary labial attached gingiva in a 32-year-old HIV-seropositive 
female with a CD4+ T cell count of 425 cells/mm3. (b) Multiple pigmented maculae of the dorsum of the tongue in a 
42-year-old HIV-seropositive female on HAART with a CD4+ T cell count of 176 cells/mm3.
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Apart from zidovudine used in the treatment of HIV infection, antimalarials, oestrogen, keto-
conazole, clofazimine, and imatinib may mediate the development of oral mucosal melanin 
hyperpigmentation [12, 38]. There will usually be a gradual diminution of the hyperpigmen-
tation after the medication is discontinued [6].
The mechanisms by which certain medications bring about oral mucosal melanin hyperpig-
mentation include upregulation of tyrosinase activity, deposition of complexes of the drug 
with pre-existing melanin in the mucosa, or induction of local inflammatory reactions with 
the triggering of melanin production [11, 38].
Histopathologically, medication-induced melanin pigmentation is characterised by the 
presence of melanin within the lamina propria either as free granules or within melano-
phages, but without melanocytic hyperplasia. Melanosis of basal cells can commonly be 
observed [11, 38].
Figure 3. Irregular, diffuse, mottled hyperpigmentation of the buccal mucosa in a 40-year-old HIV-seropositive male 
with a CD4+ T cell count of 240 cells/mm3.
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6.5. Oral mucosal melanin hyperpigmentation associated with syndromes 
and systemic diseases
Oral mucosal melanin hyperpigmentation is often observed in the systemic conditions such as 
Peutz-Jegher syndrome, McCune-Albright syndrome, Laugier-Hunziker syndrome, Addison 
disease, and neurofibromatosis. The clinical appearance is one of the brown to black spots or 
macules, with a histopathological increase in melanin in the basal cell layer of the oral epi-
thelium and melanin incontinence in the upper portion of the lamina propria, but without an 
increase in the number of melanocytes [11, 39, 40].
6.6. Oral melanotic macules
An oral melanotic macule, by conventional definition is a focal, well-defined, uniformly 
coloured oral mucosal hyperpigmentation, less than 1 cm in diameter, of unknown aetiology. 
The colour of the macule may range from light to dark brown. Any part of the oral mucosa 
may be affected, but particularly the buccal mucosa, and although they are usually solitary, 
there are sometimes several oral melanotic macules. The average age at diagnosis is 43 years, 
and it is observed more commonly in females than in males [11, 13, 36, 40]. Any recently 
developed oral melanotic maculae that are irregularly pigmented or have recently increased 
in size should be viewed with suspicion and microscopically examined to exclude melanoma; 
and melanotic maculae of the maxillary gingiva or the palatal mucosa which are the most 
common sites of melanoma should be viewed with even greater suspicion [34, 41].
6.7. Oral melanoacanthoma
Oral melanoacanthoma, mainly seen on the buccal mucosa of young Black women, is an 
uncommon, asymptomatic, brown to black melanotic lesion, reactive in origin, usually flat 
or slightly elevated with a smooth surface. It usually increases rapidly in size to several cen-
timetres and is characterised by acanthosis and spongiosis of the affected epithelium with 
dendritic melanocytes dispersed throughout the thickness of the epithelium, with a mild 
inflammatory cell infiltrate in the superficial lamina propria [11, 13, 34]. As the appearance of 
oral melanoacanthoma is not diagnostic, diagnosis must be established histopathologically.
6.8. Oral mucosal melanotic naevus (naevomelanocytic naevus)
Broadly, the term oral naevus refers to a congenital or acquired melanotic pigmentation of the 
oral mucosa brought about by abnormal excessive accumulation of melanocytes/naevomela-
nocytes at the junction of the epithelium and the lamina propria or in the lamina propria [34]. 
The sequence of biological events leading to the development of oral naevomelanocytic naevi 
is largely unknown. It is suggested that oral naevomelanocytes, like oral melanocytes, are 
derived from neural crest precursor cells, which during embryogenesis migrate to a final des-
tination in the basal cell layer of the oral epithelium. However, it is not clear which one of sev-
eral mechanisms are implicated in the development of melanocytic naevi. Naevomelanocytes 
may originate from melanocyte precursors that have acquired some genetic alterations dur-
ing development, consequently preventing them from differentiation into mature functioning 
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melanocytes in the basal cell layer of the oral epithelium; they may originate from mature 
melanocytes residing in the basal cell layer of the epithelium that have undergone some cyto-
genetic alterations culminating in their dedifferentiation into naevomelanocytes or they may 
originate from stem/progenitor melanocytes that have undergone cytogenetic alteration in 
the process of replacing mature melanocytes in the epithelium lost to mechanical, thermal, or 
chemical injury or as a result of apoptotic processes. A further possible mechanism is that nae-
vomelanocytes originate from neural crest cells destined to become melanocytes in the oral 
epithelium, but for reasons unknown remain entrapped in the submucosa. Naevomelanocytic 
naevi may thus be manifestations of a developmental malformation or of hyperplasia of mela-
nocytes [34, 42].
As many naevomelanocytes in cutaneous naevi show activating mutations in the BRAF or 
in the NRAS intracellular signalling pathways which mediate cell proliferation and differ-
entia-tion [11, 34, 42], naevi are considered by many to be benign naevomelanocytic neo-
plasias. Histopathologically, naevomelanocytic naevi are characterised by several directly 
contacting naevomelanocytes in clusters confined to the junction of the epithelium and the 
lamina propria (junctional naevi), to both junctional zone and to the superficial lamina pro-
pria (compound naevi), or only to the subepithelial connective tissue (intra-lamina proprial 
naevi). The naevomelanocytes within all three types of naevi are devoid of melanosome-
transferring dendritic processes, so that the colour of these naevomelanocytic naevi derives 
entirely from the melanosome content of the melanocytes themselves. Most oral mucosal 
melanocytic naevi are acquired rather than congenital and are of the intra-lamina proprial 
type [11, 13, 34, 36, 43].
Acquired oral mucosal melanocytic naevi are uncommon, occur more frequently in females than 
in males, and are observed mainly on the hard palate, gingiva, and buccal mucosa. The mean 
age at diagnosis is 35 years. They are small, well-defined asymptomatic macules or papules, 
usually brown to black in colour (Figure 4), but sometimes may be bluish-grey [11, 13, 36, 40].
The blue naevus is a less common oral mucosal naevus. The clinical appearance is of small 
blue macules or papules almost always on the palates of children or young adults (Figure 5) 
[34] and is characterised histopathologically by spindle-shaped melanin-producing naevome-
lanocytes arranged in fascicles parallel to the overlying epithelium, deep within the lamina 
propria [11, 13, 34].
6.9. Oral mucosal melanoma
Oral mucosal melanoma is an uncommon malignancy accounting for only about 0.5% of all 
oral cancers. It is rapidly growing and usually asymptomatic, so it is often diagnosed only 
when the melanomatous lesions are already advanced and there has been metastatic spread 
to the regional lymph nodes. Under these circumstances, the prognosis is poor with a mean 
5-year survival rate of 15–20% [15, 44]. Large clinical size, microscopical evidence of deeply 
invasive front, a high mitotic rate of the melanoma cells, lymph node metastasis, and vascular 
or neural invasion and spread are all indicators of poor prognosis [45, 46].
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The palate and the gingiva are the oral mucosal sites most frequently affected. Up to one-third 
of oral mucosal melanomata arise from pre-existing benign oral mucosal hyperpigmentations 
[15, 47–49] and the remaining two-thirds arise de-novo [15, 44, 50, 51].
Oral mucosal melanoma differs from cutaneous melanoma in its profile of cytogenetic 
alterations, its more aggressive clinical course and the fact that it is not associated with any 
known carcinogenic agents or extrinsic risk factors [15]. The oral lesions are usually irregu-
larly shaped melanotic macules, papules, plaques, or a combination of these forms, and their 
pigmentation is non-uniform, with mottled shades of grey, dark blue, dark brown, or black 
(Figure 6a–c) [15, 44].
The melanoma precursor most probably originates from a stem/progenitor cell that has 
undergone cytogenetic alterations and consequently expresses dysregulated developmental 
signalling pathways and transcription factors, ultimately acquiring a malignant phenotype. 
However, it is also possible that melanoma precursor cells originate from mature melanocytes 
in the basal cell layer of the epithelium that have undergone dedifferentiation following cytoge-
netic alterations or from immature melanocytes/naevomelanocytes arrested in the submucosa 
during migration from the neural crest which for reasons unknown have acquired a malignant 
phenotype [15].
The acquired genetic alterations confer upon the initially transformed atypical melanocytes 
and later upon the melanoma cells that evolved, a selective advantage over their neighbour-
ing normal cells in terms of fitness and proliferation. Melanoma cells then have the capacity 
Figure 4. A 20-year-old male had this melanotic lesion of the lower labial mucosa, self-reportedly since birth. It was 
probably a congenital naevus but the patient refused biopsy. Note also the physiological gingival melanosis.
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to undergo clonal expansion to invade and destroy local tissues, to metastasize to regional 
lymph nodes, and to spread to the lungs, bone, liver, brain, or skin [15, 52–54].
Melanoma cells arising from the immature melanocytes that have become arrested in the lam-
ina propria of the oral mucosa proliferate, forming nodular aggregates in the lamina propria/
submucosa with or without breaching the subepithelial basement membrane. Oral mucosal 
melanoma arising from melanocytes residing in the basal cell layer of the oral epithelium, 
on the other hand, give rise to three transient histopathological patterns: an epithelial in-situ 
pattern characterised by radial growth within the oral epithelium; an invasive pattern char-
acterized by nodular aggregates of infiltrating epithelial melanoma cells within the lamina 
propria; and a combined form in which both junctional and nodular patterns occur [15, 55, 
56]. Ultimately if not treated, all three patterns will become deeply invasive and metastatic.
Although the pathogenesis of oral mucosal melanoma is incompletely understood as yet, mel-
anin, intermediates of melanin synthesis, and MC1R genetic polymorphism play roles in the 
pathogenesis of some cases of oral mucosal melanoma [57, 58]. Certain MC1R variants reduce 
the capacity for repair to damaged DNA [5], while the process of melanin biosynthesis, par-
ticularly of pheomelanin, may itself generate reactive oxygen species and other by-products 
that may be cytotoxic, genotoxic, or mutagenic causing DNA damage [4, 6].
It has been demonstrated that in some cases of oral mucosal melanoma, there is loss of the 
integrity of the melanosomal membrane with leakage into the cytoplasm and nucleoplasm of 
Figure 5. A blue naevus (arrow) on the soft palate in a 35-year-old male. Patient was unaware of its presence, and it was 
observed on routine oral examination. Histopathological examination confirmed the clinical diagnosis of blue naevus.
Melanin20
the melanocytes, of toxic melanin particles, intermediates of melanogenesis and reactive oxy-
gen species, with consequent DNA damage and increase in the risk of genetic mutations [59]. 
Furthermore, when leaked into the extracellular microenvironment, the intermediate metabo-
lites of melanogenesis, which are also immunosuppressive, may promote evasion of immune 
responses by the initially transformed melanocyte precursors and their offspring melanoma 
cells, increasing the risk of melanomagenesis and melanoma growth [60].
Some oral mucosal melanomata are amelanotic, but most are heavily to very heavily mela-
nin-pigmented. It is unknown whether the abnormally increased biosynthesis of melanin is 
the outcome of an early biopathological process in the development of oral mucosal mela-
noma, playing a role in the initial transformational events of melanocytes, or whether it is a 
manifestation of a malignant phenotype arising subsequently to the malignant transforma-
tion of normal melanocytes. As stated above, it has been reported that up to one-third of oral 
mucosal melanoma arise within fields of benign melanin hyperpigmentation [15, 47–49]. If 
this is true, then it is likely that either the upregulated process of melanin biosynthesis, the 
increased amount of melanin in the melanocytes, or both, occurring in the fields of benign 
oral melanin hyperpigmentation, constitute risk factors for transformation into oral mucosal 
melanomata.
Figure 6. A 56-year-old black female with histologically confirmed melanoma of the hard palate and maxillary gingiva 
(a–c) of 3-year duration. It developed from a pigmented ‘patch’ of the buccal gingiva (reproduced with permission from 
Tlholoe et al. [15]).
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Thus, in a nutshell, it is possible that the initial DNA damage that predisposes melanocytes 
to malignant transformation and cytogenetic alterations that later promote actual malignant 
transformation of the initially transformed melanocytes may be driven by dysregulation in 
melanin biosynthesis and by the increased cellular content of melanin [10].
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